|
Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators |
Dec 2024 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Current and emerging strategies for management of myelodysplastic syndromes |
Dec 2020 |
Blood reviews |
Myelodysplastic Syndromes (MDS) |
|
Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape |
Dec 2024 |
Immunotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Controversies on the Consequences of Iron Overload and Chelation in MDS |
May 2020 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
Aug 2020 |
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
|
Considerations for Drug Development in Myelodysplastic Syndromes |
Jul 2023 |
Clinical Cancer Research |
Myelodysplastic Syndromes (MDS) |
|
Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia |
Jan 2019 |
Biol Blood Marrow Transplant |
Aplastic Anemia |
|
Consensus recommendations for severe aplastic anemia |
Nov 2024 |
Blood Advances |
Aplastic Anemia |
|
Consensus Recommendations for Severe Aplastic Anemia |
Aug 2024 |
Blood Advances |
Aplastic Anemia |
